Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 6:07 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 1,229 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: TBL 12 Clear all

Conditions: Irritable Bowel Syndrome
Interventions: Olorinab, Placebo; Drug
Lead sponsor: Arena Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 69
States / cities: Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 60 more

Conditions: Hepatitis C
Interventions: Pegylated Interferon Alfa 2a, Telaprevir, Ribavirin, Placebo; Biological · Drug · Other
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 1,095 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 65
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 48 more

Conditions: Hyperlipidemias
Interventions: Bempedoic Acid + Ezetimibe Fixed-Dose Combination, Bempedoic Acid, Ezetimibe, Placebos; Combination Product · Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 382 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 5
States / cities: Ames, Iowa • Nashua, New Hampshire • Statesville, North Carolina + 2 more

Conditions: Sleep Initiation and Maintenance Disorders
Interventions: volinanserin (M100907), Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 848 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Major Depressive Disorder
Interventions: Vortioxetine; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 25
States / cities: Costa Mesa, California • Culver City, California • Glendale, California + 22 more

Conditions: Contraception, Change in Bone Mineral Density
Interventions: Drospirenone; Drug
Lead sponsor: Insud Pharma; Industry
Eligibility: 13 Years to 45 Years · Female only
Enrollment: 1,542 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 46
States / cities: Alabaster, Alabama • Birmingham, Alabama • Tucson, Arizona + 36 more

Conditions: Diabetes Mellitus, Type 2
Interventions: GSK189075, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 65
States / cities: Mesa, Arizona • Artesia, California • Buena Park, California + 54 more

Conditions: Cystic Fibrosis
Interventions: ELX/TEZ/IVA, IVA; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 33
States / cities: Tucson, Arizona • Long Beach, California • Palo Alto, California + 28 more

Conditions: Emotion Regulation Difficulties, Risky Behaviors
Interventions: iTRAC; Behavioral
Lead sponsor: University of Oregon; Other
Eligibility: 10 Years to 15 Years
Enrollment: 990 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Bethel, Oregon • Springfield, Oregon

Conditions: Healthy
Interventions: dolutegravir; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 49 Years · Male only
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Acute Myeloid Leukaemia (AML), Leukemia, Blood Cancer, Blood Cancers
Interventions: Tagraxofusp, Azacitidine (AZA), Venetoclax; Drug
Lead sponsor: Jacqueline Garcia, MD; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Primary Biliary Cirrhosis
Interventions: Obeticholic Acid (OCA), Placebo; Drug
Lead sponsor: Intercept Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 15
States / cities: Sacramento, California • San Diego, California • Aurora, Colorado + 11 more

Conditions: Schizophrenia
Interventions: BI 425809, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 28
States / cities: Little Rock, Arkansas • Rogers, Arkansas • Encino, California + 24 more

Conditions: Diabetic Nephropathies
Interventions: PF-00489791, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 63
States / cities: Huntsville, Alabama • Glendale, Arizona • Tempe, Arizona + 46 more

Conditions: Primary Biliary Cholangitis
Interventions: Cilofexor, Placebo to match cilofexor; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 13
States / cities: Sacramento, California • Aurora, Colorado • Lakewood Rch, Florida + 9 more

Conditions: Eosinophilic Esophagitis
Interventions: Vonoprazan, Placebo; Drug
Lead sponsor: Phathom Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 41
States / cities: Little Rock, Arkansas • Chula Vista, California • Los Angeles, California + 35 more

Conditions: Snakebite, Envenoming, Snake
Interventions: Varespladib intravenous form, varespladib-methyl- oral form, Placebo intravenous form, Placebo - oral form; Drug
Lead sponsor: Ophirex, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 10
States / cities: Phoenix, Arizona • Tucson, Arizona • Palm Springs, California + 7 more

Conditions: Chronic Hepatitis C Virus
Interventions: LDV/SOF, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Parkinson Disease
Interventions: Donepezil (Aricept); Drug
Lead sponsor: University of Virginia; Other
Eligibility: 40 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: PTSD
Interventions: TNX-102 SL; Drug
Lead sponsor: Tonix Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 22
States / cities: Tuscaloosa, Alabama • Phoenix, Arizona • Imperial, California + 19 more

Conditions: Schizophrenia
Interventions: Paliperidone ER, Placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 10
States / cities: Cerritos, California • Fountain Valley, California • San Diego, California + 7 more

Conditions: Episodic Migraine
Interventions: Atogepant, Placebo; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 910 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 138
States / cities: Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 112 more

Conditions: Congenital Adrenal Hyperplasia, 21-OHD
Interventions: Tildacerfont; Drug
Lead sponsor: Spruce Biosciences; Industry
Eligibility: 2 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 13
States / cities: Sacramento, California • San Diego, California • Chicago, Illinois + 10 more

Conditions: Atopic Dermatitis
Interventions: Upadacitinib, Dupilumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 699 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 31
States / cities: Little Rock, Arkansas • Palo Alto, California • Sacramento, California + 27 more

Search by objective public record fields.

Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)

A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)

A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy

Efficacy and Safety of M100907 on Sleep Maintenance Insomnia With a Sub-study in Stable Type II Diabetes Mellitus

Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive Disorder

Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females

Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive

Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy

Emotion Regulation for Middle Schoolers

GSK1349572 Exposure in Blood, Seminal Fluid, and Rectal Fluid and Tissue in Healthy Male Subjects

A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis

This Study Tests Whether BI 425809 Together With Brain Training Using a Computer Improves Mental Functioning in Patients With Schizophrenia

A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis

A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks

Broad-spectrum Rapid Antidote: Varespladib IV to Oral Trial for Snakebite (BRAVIO)

Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects

Investigating the Cholinergic Contribution to Gait Dysfunction in Parkinson's Disease

Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related Conditions

A Double-blind, Placebo-controlled Study of the Safety and Efficacy of Paliperidone Extended Release (ER) in the Treatment of Schizophrenia in Adolescent Patients

12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine

A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children Aged 2-17 Years With CAH

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis